Trevor Hallam
2018 - SUTRO BIOPHARMA
In 2018, Trevor Hallam earned a total compensation of $4.4M as Chief Scientific Officer at SUTRO BIOPHARMA, a 548% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $202,900 |
|---|---|
| Option Awards | $2,951,998 |
| Salary | $405,800 |
| Stock Awards | $702,465 |
| Other | $132,000 |
| Total | $4,395,163 |
Hallam received $3M in option awards, accounting for 67% of the total pay in 2018.
Hallam also received $202.9K in non-equity incentive plan, $405.8K in salary, $702.5K in stock awards and $132K in other compensation.
Rankings
In 2018, Trevor Hallam's compensation ranked 2,446th out of 14,244 executives tracked by ExecPay. In other words, Hallam earned more than 82.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,446 out of 14,244 | 83rd |
Division Manufacturing | 900 out of 5,762 | 84th |
Major group Chemicals And Allied Products | 305 out of 2,125 | 86th |
Industry group Drugs | 247 out of 1,814 | 86th |
Industry Biological Products, Except Diagnostic Substances | 52 out of 339 | 85th |
Source: SEC filing on April 25, 2019.
Hallam's colleagues
We found two more compensation records of executives who worked with Trevor Hallam at SUTRO BIOPHARMA in 2018.
News
SUTRO BIOPHARMA CEO William Newell's 2021 pay jumps 161% to $5.6M
April 22, 2022
SUTRO BIOPHARMA CEO William Newell's 2020 pay falls 44% to $2.2M
April 29, 2021
SUTRO BIOPHARMA CEO William Newell's 2019 pay falls 56% to $3.8M
April 24, 2020
SUTRO BIOPHARMA CEO William Newell's 2018 pay jumps 1,136% to $8.7M
April 25, 2019